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Baseline characteristics of the 4011 patients recruited into the ‘Efficacy of Nitric
Oxide in Stroke’ (ENOS) trial
ENOS Investigators†
Background High blood pressure is common in acute stroke
and associated with a worse functional outcome. Many
patients who present with acute stroke are taking prescribed
antihypertensive therapy before their stroke.
Aims ENOS tested whether lowering blood pressure and con-
tinuing pre-stroke antihypertensive therapy are each safe and
effective.
Methods This study is an international multi-centre prospec-
tive randomized single-blind blinded-endpoint parallel-group
partial-factorial controlled trial of transdermal glyceryl trini-
trate (a nitric oxide donor, given for seven-days) vs. no glyceryl
trinitrate, and of continuing vs. stopping (temporarily for
seven-days) pre-stroke antihypertensive drugs if relevant, in
patients with acute ischaemic stroke or intracerebral haemor-
rhage and high systolic blood pressure (140–220 mmHg).
Results Recruitment ran from July 2001 to October 2013. Four
thousand eleven patients [2097 (52·3%) in the continue/stop
arm] were recruited from 173 sites across 23 countries in 5
continents (Asia 14%, Continental Europe 16%, UK 64%).
Baseline characteristics include: mean age 70 (standard devia-
tion 12) years; male 57%; mean time from stroke to recruit-
ment 26 (13) h; mean severity (Scandinavian Stroke Scale) 34
(13) of 58; mean blood pressure 167 (19)/90 (13) mmHg; ischae-
mic stroke 83%; and intracerebral haemorrhage 16%. The
main trial results will be presented in May 2014. The results
will also be presented in updated Cochrane systematic reviews
and included in individual patient data meta-analyses of all
relevant randomized controlled trials.
Conclusion ENOS is a large completed international trial of
blood pressure management in acute stroke and includes
patients representative of many stroke services worldwide.
Key words: acute stroke, antihypertensive drugs, blood pressure, glyceryl
trinitrate, nitric oxide, randomized controlled trial
Introduction
High systolic blood pressure (SBP > 140 mmHg) is present in
70% or more of patients with acute ischaemic stroke (IS) and
intracerebral haemorrhage (ICH) (1). Affected patients have a
worse outcome, whether judged as early recurrence, death within
a few weeks, or combined death and dependency after several
months (1–4). Lowering blood pressure (BP) might therefore
reduce these events and improve functional outcome, provided
that cerebral perfusion is not critically reduced. As a result of this
uncertainty, guidelines are not definitive about the management
of BP in acute stroke (5). The recent observation that intensive
lowering of BP in hyperacute ICH may improve outcome (6)
raises the possibility that optimal BP management may vary
between IS and ICH.
Nitric oxide (NO) donors are candidate treatments for acute
stroke; NO is a cerebral and systemic vasodilator, modulates vas-
cular and neuronal function, and inhibits apoptosis (7). Preclini-
cal studies of cerebral ischemia have found that NO donors
reduce stroke lesion size and improve regional cerebral blood flow
(CBF) and functional outcome (8). Five small clinical studies of
NO donors in patients with acute or recent stroke have been
performed. Intravenous sodium nitroprusside reduced BP
without altering CBF and exhibited antiplatelet effects (thereby
precluding its use in ICH) (9). Four pilot trials of transdermal
glyceryl trinitrate (GTN) found that it lowered BP by approxi-
mately 8% (albeit with tachyphylaxis developing over the first
week of treatment), did not alter platelet function (and so could
be given in ICH), did not alter middle cerebral artery blood flow
velocity or regional CBF, improved aortic vascular compliance,
and could be given to patients with dysphagia (10–13). In one
small trial, functional outcome was improved with GTN when
given within 4 h of stroke onset (13). Overall, GTN was feasible to
administer and appeared safe (10–18).
In addition to the question of whether BP should be lowered
during the acute phase of stroke, a separate question is whether
antihypertensive agents taken at home before the stroke should be
continued or stopped during the acute and sub-acute period after
stroke (19). The COSSACS trial intended to address this question
in 2900 patients but low recruitment meant that only 763 patients
were able to be recruited (20,21). This question remains clinically
important and was incorporated into ENOS for relevant patients.
Methods
Eligibility and consent
The full inclusion and exclusion criteria are given in the published
protocol (22) and in the latest version of the protocol (Supporting
Information Appendices S1 and S2). Adult patients with acute
ischaemic or haemorrhagic stroke were eligible if they were pre-
viously independent [modified Rankin Scale (mRS) 0–2], con-
scious (Glasgow Coma Scale > 8), had residual limb weakness,
had SBP between 140–220 mmHg, and were within 48 h of onset.
The investigator had to be uncertain about whether BP should be
lowered in acute stroke and whether pre-stroke antihypertensive
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medication (if being taken) should be continued or stopped tem-
porarily. Patients gave written informed consent prior to enroll-
ment; if they lacked capacity (e.g. due to drowsiness, dysphasia, or
confusion) then a relative could give proxy consent. Proxy consent
by an independent physician was also permissible if allowed by
local site regulations. Patients had a computed tomography or
magnetic resonance imaging (MRI) brain scan pre- or soon after
randomization, and a repeat brain scan at seven-days, where pos-
sible or if there was any neurological deterioration.
Randomization and data collection
After informed consent had been obtained, the clinician used the
secure web-based randomization system to enter a patient into
the study. The system recorded baseline characteristics of the
patients, validated data with range and consistency checks, and
then allocated the patient to treatment. To achieve optimal base-
line matching between treatment groups and ensure concealment
of allocation, randomization incorporated stratification (country,
stroke type, use of pre-stroke antihypertensive drugs) and mini-
mization (on baseline prognostic factors, as highlighted in
Table 1); the minimization algorithm included a random element
(simple randomization) in 5% of patients. Stratification and
minimization allow for improved matching at baseline, minimi-
zation increases statistical power (24), and simple randomization
reduces predictability. Following randomization, the investigator
was informed of the patient’s treatment allocation: to GTN or no
GTN for one-week and if relevant to continue or stop pre-stroke
antihypertensive drugs for one-week. The minimization variables
will be used for adjustment of the primary and secondary analyses
(25), as recommended (24).
Outcomes
The primary and main secondary outcomes were collected cen-
trally at day 90 by an assessor in each country who was blinded to
treatment. In most territories, they first contact the general prac-
titioner to check that the patient is still alive, and then telephone
the patient (and carer as appropriate). Where telephone contact
cannot be made, outcome information was collected using a
postal questionnaire. Final stroke diagnosis was determined from
the local investigator diagnosis and blinded central scan adjudi-
cation of the brain imaging data. The primary outcome was the
mRS at day 90; secondary outcomes include early events at day 7;
measures of disability, cognition, mood, and quality of life at day
90; death; and the effect of BP lowering on infarct swelling at 7
days in patients with follow-up scans (22).
Use of the Internet
The trial was the first acute stroke trial in the world to use the
Internet to randomize and collect data in real time online:
• Trial website: http://www.enos.ac.uk/
• Secure website for real-time data entry, validation, and
randomization: http://www.nottingham.ac.uk/~nszwww/enos/
enostrialdb/
• Demo website for investigators to practice data entry: https://
www.nottingham.ac.uk/~nszwww/enos/enostrialdb-demo/enos
_login.php (log-in: demoinv1, password: nottingham; pin: 8888)
Progress with the study and modifications to
the design
Planning for ENOS commenced in 2000 following the results of
the first two pilot randomized controlled trials of GTN (10,11).
The trial has had multiple phases and funding:
• Initial phase (July 2001 to March 2004): funding from Division
of Stroke, University of Nottingham UK and a bequest from the
Reichstadt Family. Two hundred twenty-one patients recruited.
• Start-up phase (April 2004 to October 2006): funding from
the Bupa Foundation, with additional support from the
Hypertension Trust. The Singapore A Star funded an MRI sub-
study in Singapore (26). Two hundred ninety-nine patients
recruited.
• Main phase (November 2006 to October 2013, with funding
through to end April 2014): funding from the UK Medical
Research Council [latterly administered by the National Institute
for Health Research (NIHR) Efficacy and Mechanism Evaluation
program]. Three thousand four hundred ninety-one patients
recruited. Initially, the aim was to recruit a total of 5000 patients,
as published in the protocol in 2006 (22). A revised sample size of
at least 3500 patients was set in April 2009 (25).
Throughout the trial, six protocol amendments were made
covering multiple issues. The key one was to optimize the method
of analysis of the primary outcome, which allowed a reduction in
sample size and is important as the recruitment rate was not
compatible with reaching the originally planned total of 5000
patients. Research in the early and mid-2000s have shown that a
binary analysis of the mRS (0–2 vs. 3–6) was sub-optimal and that
statistical power could be increased by incorporating all seven
individual mRS scores in the analysis and then comparing the
distribution in mRS between the treatment groups (27). This
approach is now recommended by the European Stroke Organi-
sation (28). A further and additional increase in statistical power
could be achieved by incorporating key prognostic baseline vari-
ables as covariates (29). These approaches were similar to findings
from other groups (30–32).
Hence, the primary analysis of the mRS in ENOS will utilize the
shift approach, as analyzed using ordinal logistic regression, with
adjustment for covariates, with comparison between treatment
groups (GTN/no GTN; continue/stop pre-stroke BP medica-
tions). The overall proposal to change the method of analysis of
the primary outcome from binary to ordinal was first presented
to, and agreed by, the Trial Steering Committee in January 2008
and confirmed in 2009; this decision was made without knowl-
edge of the unblinded data. A draft statistical analysis plan (SAP),
highlighting this change, was posted on the trial website in April
2009. The final SAP was submitted for publication in 2013 prior
to the planned unblinding of the data in early 2014 (25).
The trial is supervised by a Trial Steering Committee and Inter-
national Advisory Committee, run by a trial management com-
mittee (based in Nottingham, UK), and was monitored by an
independent data monitoring committee (DMC) (Supporting
Information Appendix S3). By the end of recruitment, the DMC
met and assessed safety and efficacy on 23 occasions. Independent
experts adjudicated brain scans and serious adverse events, and
were blinded to treatment.
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Table 1 Clinical characteristics at randomization
Variable All patients (GTN/No GTN) Continue-stop Not in continue-stop
No. of patients (%) 4011 (100) 2097 (52·3) 1914 (47·7)
Age (years)
Mean (SD)* 70·3 (12·2) 72·9 (11·2) 67·4 (12·6)
18 (%)§ 0 (0·0) 0 (0·0) 0 (0·0)
18–40 (%) 39 (1·0) 11 (0·5) 28 (1·5)
41–50 (%) 239 (6·0) 68 (3·2) 171 (8·9)
51–60 (%) 606 (15·1) 237 (11·3) 369 (19·3)
61–70 (%) 986 (24·6) 458 (21·8) 528 (27·6)
71–80 (%) 1284 (32·0) 755 (36·0) 529 (27·6)
81–90 (%) 758 (18·9) 511 (24·4) 247 (12·9)
91–100 (%) 99 (2·5) 57 (2·7) 42 (2·2)
>100 (%) 0 (0·0) 0 (0·0) 0 (0·0)
Gender
Male (%)* 2297 (57·3) 1068 (50·9) 1229 (64·2)
Female (%) 1714 (42·7) 1029 (49·1) 685 (35·8)
Geographical region†
Africa 148 (3·7) 71 (3·4) 77 (4·0)
America, north 33 (0·8) 14 (0·7) 19 (1·0)
Asia, east 107 (2·7) 41 (2·0) 66 (3·4)
Asia, south 267 (6·7) 74 (3·5) 193 (10·1)
Asia, south-east 185 (4·6) 87 (4·1) 98 (5·1)
Australasia 79 (2·0) 51 (2·4) 28 (1·5)
British Isles 2555 (63·7) 1354 (64·6) 1201 (62·7)
Europe, mainland 637 (15·9) 405 (19·3) 232 (12·1)
Time of stroke randomization (hours)
Mean (SD)* 26·0 (12·9) 25·6 (12·9) 26·4 (12·8)
Median [IQR] 26·0 [20·6] 25·7 [20·0] 26·5 [20·6]
<1 (%)§ 0 (0·0) 0 (0·0) 0 (0·0)
1–6 (%) 273 (6·8) 143 (6·8) 130 (6·8)
7–12 (%) 438 (10·9) 241 (11·5) 197 (10·3)
13–18 (%) 470 (11·7) 267 (12·7) 203 (10·6)
19–24 (%) 597 (14·9) 304 (14·5) 293 (15·3)
25–36 (%) 1203 (30·0) 629 (30·0) 574 (30·0)
37–48 (%) 1015 (25·3) 509 (24·3) 506 (26·4)
>48 (%)§ 15 (0·4) 4 (0·2) 11 (0·6)
Hemodynamics
Systolic BP (mmHg)
Mean (SD)* 167·2 (19·0) 167·1 (18·8) 167·4 (19·1)
<140 (mmHg) 168 (4·2) 85 (4·1) 83 (4·3)
140–160 (mmHg) 1439 (35·9) 764 (36·4) 675 (35·3)
161–180 (mmHg) 1434 (35·8) 739 (35·2) 695 (36·3)
181–200 (mmHg) 723 (18·0) 379 (18·1) 344 (18·0)
201–220 (mmHg) 238 (5·9) 125 (6·0) 113 (5·9)
>220 (mmHg) 9 (0·2) 5 (0·2) 4 (0·2)
Diastolic BP, mean (mmHg) 89·5 (13·1) 88·3 (13·1) 90·9 (13·1)
Heart rate, mean (bpm) (n = 4007) 77·5 (14·7) 77·1 (15·2) 77·9 (14·2)
Atrial fibrillation (%)
Current/previous history 571 (14·2) 459 (21·9) 112 (5·9)
On ECG 665 (16·6) 487 (23·2) 178 (9·3)
Any (%) 762 (19·0) 566 (27·0) 196 (10·2)
Qualifying event (%)*¶
Ischaemic stroke 3342 (83·3) 1832 (87·4) 1510 (78·9)
Intracerebral haemorrhage 629 (15·7) 246 (11·7) 383 (20·0)
Stroke type unknown 1 (0·1) 1 (0·1) 0 (0·0)
Not stroke 39 (1·0) 18 (0·9) 21 (1·1)
Unknown (no form submitted) 0 (0·0) 0 (0·0) 0 (0·0)
Scandinavian Stroke Scale (/58) Σ
Mean (SD)* 33·7 (13·2) 32·9 (13·4) 34·6 (12·8)
Median [IQR] 36·0 [20·0] 35·0 [21·0] 37·0 [19·0]
51–58 337 (8·4) 165 (7·9) 172 (9·0)
41–50 1134 (28·3) 558 (26·6) 576 (30·1)
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Table 1 Continued
Variable All patients (GTN/No GTN) Continue-stop Not in continue-stop
31–40 1014 (25·3) 534 (25·5) 480 (25·1)
21–30 778 (19·4) 399 (19·0) 379 (19·8)
11–20 453 (11·3) 270 (12·9) 183 (9·6)
0–10 295 (7·4) 171 (8·2) 124 (6·5)
NIHSS (/42), calculated (23) 11·2 (5·7) 11·5 (5·8) 10·8 (5·5)
Glasgow Coma Scale [/15]
Mean (SD) 14·2 (1·5) 14·1 (1·6) 14·3 (1·5)
Median [IQR] 15·0 [1·0] 15·0 [1·0] 15·0 [1·0]
15 2782 (69·4) 1370 (65·3) 1412 (73·8)
14 432 (10·8) 262 (12·5) 170 (8·9)
13 175 (4·4) 104 (5·0) 71 (3·7)
12 219 (5·5) 128 (6·1) 91 (4·8)
11 197 (4·9) 116 (5·5) 81 (4·2)
10 120 (3·0) 71 (3·4) 49 (2·6)
9 86 (2·1) 46 (2·2) 40 (2·1)
<9§ 0 (0·0) 0 (0·0) 0 (0·0)
OCSP classification (%)
Total anterior* 1209 (30·1) 697 (33·2) 512 (26·8)
Partial anterior 1251 (31·2) 702 (33·5) 549 (28·7)
Lacunar 1397 (34·8) 624 (29·8) 773 (40·4)
Posterior 154 (3·8) 74 (3·5) 80 (4·2)
Medical history (%)
Hypertension 2607 (65·0) 1994 (95·1) 613 (32·0)
Treated hypertension† 2138 (53·3) 2086 (99·5) 52 (2·7)
Hyperlipidemia 1098 (27·4) 808 (38·5) 290 (15·2)
Diabetes mellitus 699 (17·4) 484 (23·1) 215 (11·2)
Stroke 594 (14·8) 416 (19·8) 178 (9·3)
Transient ischaemic attack 544 (13·6) 352 (16·8) 192 (10·0)
Ischaemic heart disease 669 (16·7) 523 (24·9) 146 (7·6)
Peripheral arterial disease 117 (2·9) 77 (3·7) 40 (2·1)
Family history of young stroke, first degree relative (n = 3878) 229 (5·9) 132 (6·5) 97 (5·2)
Smoking (%) (n = 3846)
Current 945 (24·6) 363 (18·2) 582 (31·5)
Past 1222 (31·8) 689 (34·5) 533 (28·9)
Never 1679 (43·7) 948 (47·4) 731 (39·6)
Alcohol, median (units per week)
>21 294 (7·3) 104 (5·0) 190 (9·9)
<21 1582 (39·4) 793 (37·8) 789 (41·2)
None 1840 (45·9) 1031 (49·2) 809 (42·3)
Premorbid modified Rankin Scale (mRS) [/2]
mRS 0 2985 (74·4) 1413 (67·4) 1572 (82·1)
mRS 1 551 (13·7) 360 (17·2) 191 (10·0)
mRS 2 473 (11·8) 322 (15·4) 151 (7·9)
mRS > 2§ 2 (0·1) 2 (0·1) 0 (0·0)
Medications (%)
BP lowering
Angiotensin-converting enzyme inhibitor 1010 (25·2) 999 (47·6) 11 (0·6)
Angiotensin receptor antagonist 348 (8·7) 337 (16·1) 11 (0·6)
Renin inhibitor 4 (0·1) 4 (0·2) 0 (0·0)
ß-receptor antagonist 838 (20·9) 820 (39·1) 18 (0·9)
Calcium channel blocker 742 (18·5) 725 (34·6) 17 (0·9)
Diuretic 755 (18·8) 735 (35·1) 20 (1·0)
α-receptor antagonist 150 (3·7) 146 (7·0) 4 (0·2)
Centrally acting 33 (0·8) 32 (1·5) 1 (0·1)
Other 23 (0·6) 23 (1·1) 0 (0·0)
BP tablets taken before onset
Mean (SD) 1·0 (1·1) 1·8 (0·9) 0·0 (0·3)
Median [IQR] 1·0 [2·0] 2·0 [1·0] 0·0 [0·0]
Mode 0·0 1·0 0·0
0 (%) 1873 (46·7) 11 (0·5) 1862 (97·3)
1 (%) 949 (23·7) 915 (43·6) 34 (1·8)
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Results
Trial delivery
Recruitment progressed with a start-up phase in a limited
number of sites, and then expanded to a main phase
(Figure 1a,b). As with any large international, investigator driven
trial with limited funding, ENOS has suffered from a number of
issues although none materially affected data integrity or validity.
These include problems with blinding, recruitment, randomiza-
tion, inappropriate treatment, and data loss (Supporting Infor-
mation Appendix S4).
Baseline characteristics
Four thousand eleven patients were recruited from 173 sites
(Table 2, Supporting Information Appendix S3) across 23 coun-
tries in 5 continents (Asia 14%, continental Europe 16%, UK
64%) over the 12-year period from July 20, 2001 to October 14,
2013. Two thousand ninety-seven (52·3%) of these patients were
also recruited into the continue/stop arm of the trial. The major-
ity of patients were entered into the trial over the latter part of the
trial, for example, from start of 2008: GTN/no GTN 3182 (79%),
continue/stop 1711 (82%) (Figure 1a,b). Around two-thirds of
patients were recruited from one-third of sites (Figure 2a,b).
Three sites (Dublin, Eire; Ragama, Sri Lanka; Nottingham, UK)
ran temporary screening logs at some point in the trial; altogether,
of 174 patients screened, 30 (17%) were enrolled.
The baseline characteristics (Table 1) are presented as number
(%), median [interquartile range], or mean (standard deviation).
Key features include: mean age 70·3 (standard deviation 12·2)
years; male 57·3%; mean time to recruitment 26·0 (12·9) h; mean
severity (Scandinavian Stroke Scale) 33·7 (13·2) of maximum 58
(estimated National Institutes of Health Stroke Scale 11 (35));
mean BP 167·2 (19·0)/89·5 (13·1) mmHg; IS 83·3%; ICH 15·7%;
stroke of unknown type 0·1%; and nonstroke 1·0%. In compari-
son with patients not taking antihypertensive agents prior to their
stroke, those patients on pre-stroke BP drugs were older, more
likely to be female, have atrial fibrillation, have had a previous
stroke and/or ischaemic heart disease, and present with an IS.
Table 3 shows univariate relationships between a number of
key baseline factors, including year of enrollment; as the trial
progressed, average age increased. In contrast, the proportion of
men, proportion of patients with haemorrhage, and severity, SBP,
and time to recruitment decreased. In other univariate analyses,
increasing age was associated with an increase in time to recruit-
ment, a decline in the proportion of males and patients with
haemorrhage, and reduced severity and SBP; males had more
severe stroke and haemorrhages but had a reduced SBP and time
Table 1 Continued
Variable All patients (GTN/No GTN) Continue-stop Not in continue-stop
2 (%) 738 (18·4) 729 (34·8) 9 (0·5)
3 (%) 341 (8·5) 335 (16·0) 6 (0·3)
4 (%) 96 (2·4) 93 (4·4) 3 (0·2)
5 (%) 13 (0·3) 13 (0·6) 0 (0·0)
6 (%) 1 (0·1) 1 (0·1) 0 (0·0)
7 (%) 0 (0·0) 0 (0·0) 0 (0·0)
Lipid lowering (n = 3972) 1217 (30·6) 882 (42·5) 335 (17·7)
Nitrate 154 (3·8) 136 (6·5) 18 (0·9)
Side of lesion, right (%) (n = 4003) 2086 (52·1) 1074 (51·3) 1012 (53·0)
TOAST classification (%) (n = 3342)‡
Cardioembolic 717 (21·5) 507 (27·7) 210 (13·9)
Large vessel 742 (22·2) 417 (22·8) 325 (21·5)
Small vessel/lacunar 1276 (38·2) 626 (34·2) 650 (43·0)
Mixed 113 (3·4) 74 (4·0) 39 (2·6)
Unknown 662 (19·8) 330 (18·0) 332 (22·0)
Temperature (°C) (n = 3894) 36·6 (0·7) 36·5 (0·7) 36·6 (0·6)
Glucose (mmol/l) (n = 3845) 7·4 (3·0) 7·5 (3·0) 7·3 (3·1)
Feeding (%)
Normal diet 1738 (43·3) 814 (38·8) 924 (48·3)
Soft diet 942 (23·5) 509 (24·3) 433 (22·6)
Nasogastric fed 225 (5·6) 103 (4·9) 122 (6·4)
PEG-fed 7 (0·2) 7 (0·3) 0 (0·0)
Intravenous/subcutaneous fluids 726 (18·1) 426 (20·3) 300 (15·7)
Nil 373 (9·3) 238 (11·3) 135 (7·1)
Thrombolysis, given* 425 (10·6) 248 (11·8) 177 (9·2)
Data are number (%), median [interquartile range], or mean (standard deviation).
*Minimization variable; †stratification variable; ‡may exceed 100%; §protocol violation; ¶final diagnosis from hospital event form at discharge or death.
Σ Scandinavian Stroke Scale (SSS): ranges from 0 (coma with quadriplegia) to 58 (normal neurological status); the similar National Institutes of Health
Stroke Scale moves in the opposite direction ranging from 0 (normal neurological status) to 42 (coma with quadriplegia).
BP, blood pressure; bpm, beats per minute; ECG, ; GTN, glyceryl trinitrate; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale;
OCSP, Oxfordshire Community Stroke Project; PEG, percutaneous endoscopic gastrostomy; SD, standard deviation; TOAST, Trial of ORG 10172 in
Acute Stroke Treatment.
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to recruitment; and increasing stroke severity was associated with
a lower SBP (Table 3). ICH was associated with less severe stroke.
Reporting of results
The database will be locked and the trial unblinded and analyzed in
early 2014, as per the SAP (25). The main results will be reported at
the European Stroke Conference in Nice in May 2014. In parallel,
separate manuscripts will be submitted addressing GTN vs. no
GTN and continue vs. stop pre-stroke antihypertensive medica-
tion.Multiple prespecified secondary publications and analyses are
also described in the SAP (25), including this paper.
Three Cochrane reviews will be updated with summary data
from ENOS:
• Nitric oxide (14)
• Interventions for deliberately altering BP in acute stroke
(BASC-1) (15)
• Vasoactive drugs for acute stroke (BASC-2) (16)
The ENOS data will also be shared with prospective individual
patient data meta-analyses:
• Glyceryl trinitrate – including GTN-1/2/3, RIGHT
(10–13)
• Continue vs. stop pre-stroke antihypertensive medications
– including COSSACS (21)
• Blood Pressure in Acute Stroke Collaboration-3 (BASC-3) –
including CATIS, COSSACS, FAST-Mag, IMAGES, INTERACT-
1/2, and SCAST (6,21,36–39)
Fig. 1 (a) Recruitment curve by time for GTN/no GTN. (b) Recruitment curve by time for continue/stop pre-stroke antihypertensive drugs. GTN, glyceryl
trinitrate.
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Discussion
With 4011 patients, ENOS is a large completed international trial
of BP management in acute stroke involving both active BP
lowering and the comparison of continuing vs. stopping pre-
stroke antihypertensive drugs. The characteristics of the patients
justify several comments. First, the wide geographical coverage
and large number of recruiting sites mean that the patients are
representative of those admitted to stroke services in many parts
of the world. Second, most patients were recruited since 2008 and
so were treated using modern clinical practice. Nevertheless, some
patient characteristics did change over time reflecting differences
in the types of patients being recruited by newer sites, for
example, increasing age, reducing proportion of males, and time
Table 2 Recruitment: number of sites and patients by region [numbers and %] and country for glyceryl trinitrate vs. none, and continue vs. stop
pre-stroke antihypertensive therapy
Regions Countries No. of sites
No. of patients (%):
GTN/no GTN %
No. of patients (%):
Continue vs. stop %
Africa [4] [148] [3·7] [71] [3·4]
Egypt 4 148 3·7 71 3·4
America, north [2] [33] [0·8] [14] [0·7]
Canada 2 33 0·8 14 0·7
Asia, east [3] [107] [2·7] [41] [2·0]
China 2 103 2·6 39 1·9
Hong Kong 1 4 0·1 2 0·1
Asia, south [10] [267] [6·7] [74] [3·5]
India 8 157 3·9 47 2·2
Sri Lanka 2 110 2·7 27 1·3
Asia, south-east [4] [185] [4·6] [87] [4·2]
Malaysia 2 14 0·4 6 0·3
Philippines 1 16 0·4 7 0·3
Singapore (26) 1 155 3·9 74 3·5
Australasia [5] [79] [2·0] [51] [2·4]
Australia 1 8 0·2 7 0·3
New Zealand 4 71 1·8 44 2·1
British Isles [116] [2555] [63·7] [1354] [64·6]
Eire 1 10 0·3 2 0·1
UK 115 2545 63·5 1352 64·5
Continental Europe [29] [637] [15·9] [405] [19·3]
Denmark 3 17 0·4 7 0·3
Georgia 3 195 4·9 152 7·3
Greece 1 12 0·3 12 0·6
Italy 3 33 0·8 22 1·1
Norway 2 4 0·1 2 0·1
Poland (33) 3 123 3·1 73 3·5
Romania (34) 3 217 5·4 111 5·3
Spain 2 8 0·2 5 0·2
Sweden 4 14 0·4 10 0·5
Turkey 5 14 0·4 11 0·5
Total 23 173 4011 100 2097 100
GTN, glyceryl trinitrate.
Table 3 Univariate correlations between baseline characteristics for age, gender, stroke severity [Scandinavian Stroke Scale (SSS)], stroke type
(ischaemic, haemorrhagic), systolic blood pressure (SBP), time to randomization, and year of randomization
Age Gender, male Severity (SSS)
Stroke type,
bleed SBP
Time to
randomization
Year of
randomization
Age X −0·213 (<0·001) −0·153 (<0·001) −0·122 (<0·001) 0·014 (0·384) 0·008 (0·627) 0·052 (0·001)
Gender −0·213 (<0·001) X 0·100 (<0·001) 0·044 (0·006) −0·033 (0·037) −0·024 (0·126) −0·003 (0·851)
Severity −0·153 (<0·001) 0·100 (<0·001) X −0·095 (0·001) −0·057 (<0·001) 0·067 (<0·001) −0·074 (<0·001)
Type −0·122 (<0·001) 0·044 (0·006) −0·095 (0·001) X 0·085 (<0·001) −0·026 (0·098) −0·023 (0·144)
SBP 0·014 (0·384) −0·033 (0·037) −0·057 (<0·001) 0·085 (<0·001) X −0·022 (0·165) −0·049 (0·002)
Time 0·008 (0·627) −0·024 (0·126) 0·067 (<0·001) −0·026 (0·098) −0·022 (0·165) X −0·248 (<0·001)
Year 0·052 (0·001) −0·003 (0·851) −0·074 (<0·001) −0·023 (0·144) −0·049 (0·002) −0·248 (<0·001) X
Correlations by point biserial or Spearman’s tests; data are regression coefficient (P value).
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to recruitment. Last, the observation that ICH was associated with
less severe stroke, although counter-intuitive, reflects that many
patients were recruited from east and south-east Asia where ICH
are often sub-cortical and therefore smaller, in contrast to large
cortical infarcts recruited from Europe. Additionally, the active
management of severe haemorrhage, for example, BP lowering or
surgery, may bias recruitment to patients with smaller hematoma.
Although ENOS is large and definitive and significant results
would help drive changes in clinical practice, it will still be
necessary to merge individual patient data from ENOS with
other large trials of lowering BP (as planned in BASC-3) to assess
fully the effects of BP management in different sub-groups of
patients.
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